No Clinically Relevant CYP3A Induction with the Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240

M100240, an acetate thioester of MDL 100,173, is a dual angiotensin‐converting enzyme/neutral endopeptidase inhibitor currently in Phase II development. M100240 and MDL 100,173 were evaluated in an in vitro cytochrome P450 human hepatocyte model for enzyme induction. Although a dose‐dependent CYP3A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2004-04, Vol.44 (4), p.379-387
Hauptverfasser:	Martin, Nancy E., Howell, Stanley R., Martin, Louis L., Cirillo, Iolanda, Barrett, Jeffrey S.
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE/NEP inhibitor Adolescent Adult Angiotensin-Converting Enzyme Inhibitors - blood Angiotensin-Converting Enzyme Inhibitors - pharmacokinetics Angiotensin-Converting Enzyme Inhibitors - pharmacology Area Under Curve Aryl Hydrocarbon Hydroxylases - biosynthesis Benzazepines - pharmacology CYP3A induction Cytochrome P-450 CYP3A drug-drug interactions Enzyme Induction Female Humans M100240 Male midazolam Midazolam - blood Midazolam - pharmacokinetics Midazolam - pharmacology Middle Aged Neprilysin - antagonists & inhibitors Oxidoreductases, N-Demethylating - biosynthesis pharmacokinetics Pyridines - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!